As of February 28, 2013, 91 subjects have been enrolled in SHINE across 24 enrolling sites. A total of 32 sites have completed readiness calls and are activated to enroll. For sites that are pending activation, we would encourage you to prioritize IRB approval, pharmacy orders and confirming laptop connectivity since these have caused delays at some sites. We very much appreciate your efforts and are here to help with the readiness process.

Our thanks to the following teams for their accomplishments during the past 3 months:

- The Emory team is leading study recruitment with 14 subjects enrolled to date.
- The Utah team is in second place with 10 enrollments, followed by NYP (9), Kentucky (7) and Temple (7).
- Temple remains the hub with the most activated spokes.
- OSU was the first new NETT hub to be activated and has enrolled their first 4 subjects in 6 weeks.
Q: We are curious what are you and other sites doing in view of the D50 National Shortage? Our hospital is facing a shortage which could affect the study protocol.

A: Due to manufacturing delays and increased demand, there is a national shortage of D50. This shortage may or may not affect your site. If your site is one that is affected the shortage, we would recommend that you work with your pharmacy to consider the use of D50 bags.

If D50 bags are not available, D10 or D25 may be used (multiply IV D50 doses by 5 for equivalent IV D10 dose or D25 and multiply IV D50 doses by 2 for the equivalent IV D25 dose). Please update your study orders and the hypoglycemia prevention and management protocol to reflect these options.

In the study laptop, record the equivalent dose of D50 administered. In the intervention group, accept the D50 dose recommendation and note the volume of D10 or D25 administered in the Comments field. In the control group, enter D50 25mL in the New entry pop up and document the volume of D10 or D25 administered in the Notes field.

Questions about updating your hypoglycemia protocol should be directed to Amy Fansler (acf7h@virginia.edu).

I-Spot Insights on Selected Procoagulation markers and Outcomes in Stroke Trial

Congratulations to the following sites that have been released to enroll for I-Spot: Kentucky, HFHS, Temple, Allegheny and Texas. Contact Hannah Reimer (hreimer@temple.edu) with questions about the ancillary trial and readiness.

Study Reminders

**Screen failure logs** - Remember that only primary ischemic strokes within 12 hours of symptom onset (or time last seen well) with a glucose greater than 110 should be reported in the SFL. Primary ICH should not be included. If your site does not have 24/7 coverage, please report any screen failures whether actively screening or not at the time of arrival. As always, screen fail logs are due on the 10th of every month. ~ Katrina van de Bruinhorst

**Laptop software updates** – Thanks to the many coordinators for such a prompt response to making the recent study laptop software updates. If we have not yet updated your laptop, please contact me to set aside time for this quick update. ~ Amy Fansler